Overcoming KRAS-Mutant Lung Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS family proteins are frequently mutated in cancer, driving tumor growth.
• Targeting KRAS mutations, particularly KRAS G12C, has been a long-standing challenge in lung cancer therapy.
• Recent advances led to the FDA approval of the first direct KRAS G12C inhibitor.

Purpose of the Study:

• To review the history of RAS protein discovery and KRAS-driven lung cancer research.
• To discuss the efficacy and limitations of the first KRAS G12C inhibitor.
• To explore resistance mechanisms and future therapeutic strategies for KRAS-altered lung cancers.

Main Methods:

• Literature review of RAS protein discovery and KRAS inhibitor development.
• Analysis of clinical trial data for KRAS G12C inhibitors.
• Discussion of molecular mechanisms of resistance and profiling techniques.

Main Results:

• The first direct KRAS G12C inhibitor shows objective response rates of 36%-45% with a 10-month median duration of response.
• Tumor non-response and acquired resistance are significant clinical challenges.
• Identified resistance mechanisms include new KRAS alterations, RTK pathway activation, bypass pathways, and transcriptional remodeling.

Conclusions:

• While the KRAS G12C inhibitor represents a breakthrough, overcoming resistance is crucial for improving patient outcomes.
• Profiling resistance mechanisms aids in selecting appropriate clinical trials.
• Future research should focus on combination therapies and targeting other KRAS alterations in lung cancer.